Related references
Note: Only part of the references are listed.Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation
Sebastian Zundler et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study
William J. Sandborn et al.
GASTROENTEROLOGY (2022)
Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Waseem Ahmed et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study
Cara De Galan et al.
JOURNAL OF CROHNS & COLITIS (2022)
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Geert D'Haens et al.
LANCET (2022)
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
Marc Ferrante et al.
LANCET (2022)
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
Lucas Guillo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Rheumatoid arthritis and inflammatory bowel disease: A bidirectional two-sample Mendelian randomization study
Christa Meisinger et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2022)
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Quazim A. Alayo et al.
CROHNS & COLITIS 360 (2022)
The four epidemiological stages in the global evolution of inflammatory bowel disease
Gilaad G. Kaplan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease
Stefan Schreiber et al.
GASTROENTEROLOGY (2021)
Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn's Disease
Antonio Tursi et al.
JOURNAL OF CROHNS & COLITIS (2021)
Characterization and Function of Tumor Necrosis Factor and Interleukin-6-Induced Osteoclasts in Rheumatoid Arthritis
Kazuhiro Yokota et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial
Maja Skov Kragsnaes et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Management of Rheumatoid Arthritis: An Overview
Andrei-Flavius Radu et al.
CELLS (2021)
Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy
Giuseppe Privitera et al.
AUTOIMMUNITY REVIEWS (2021)
The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
Neeraj Narula et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease
Flavia Maria Pavel et al.
DIAGNOSTICS (2021)
Reframing Immune-Mediated Inflammatory Diseases
Nada Boutrid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease
Michael T. Dolinger et al.
INFLAMMATORY BOWEL DISEASES (2021)
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
Vince B. C. Biemans et al.
JOURNAL OF CROHNS & COLITIS (2020)
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Normal human enthesis harbours conventional CD4+and CD8+T cells with regulatory features and inducible IL-17A and TNF expression
Abdulla Watad et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Paradoxical gastrointestinal effects of interleukin-17 blockers
Marine Fauny et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis (vol 16, pg 415, 2020)
Eric Gracey et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis
Mohammad H. Derakhshan et al.
RMD OPEN (2020)
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)
Silvio Danese et al.
GUT (2019)
Expansion of IL-23 receptor bearing TNFR2+T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease
Heike Schmitt et al.
GUT (2019)
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
Christian Maaser et al.
JOURNAL OF CROHNS & COLITIS (2019)
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study
Daniela Pugliese et al.
DIGESTIVE AND LIVER DISEASE (2019)
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study
Claire Liefferinckx et al.
JOURNAL OF CROHNS & COLITIS (2019)
HLA Alleles Associated With Risk of Ankylosing Spondylitis and Rheumatoid Arthritis Influence the Gut Microbiome
Mark Asquith et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
Sophie Glatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Markus F. Neurath
NATURE IMMUNOLOGY (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Comorbid immune-mediated diseases in inflammatory bowel disease: a nation-wide population-based study
Sung-Wook Park et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis
C. Felice et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)
Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data
Stephanie Coward et al.
GASTROENTEROLOGY (2019)
The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy
C. R. H. Hedin et al.
JOURNAL OF CROHNS & COLITIS (2019)
Host-microbiota interactions in rheumatoid arthritis
Yuichi Maeda et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: A systematic review and meta-analysis
Goncalo Boleto et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Desiree van der Heijde et al.
JOURNAL OF RHEUMATOLOGY (2018)
ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Effects of HLA-B27 on Gut Microbiota in Experimental Spondyloarthritis Implicate an Ecological Model of Dysbiosis
Tejpal Gill et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases
Carla Felice et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis
Isabelle Cambre et al.
NATURE COMMUNICATIONS (2018)
Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study
Ulf Lindstrom et al.
RMD OPEN (2018)
Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis
Stefano Alivernini et al.
RMD OPEN (2018)
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
Stephan R. Vavricka et al.
INFLAMMATORY BOWEL DISEASES (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts
Alessandro Armuzzi et al.
DIGESTIVE AND LIVER DISEASE (2017)
Faecal microbiota study reveals specific dysbiosis in spondyloarthritis
Maxime Breban et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis
Francesco Ciccia et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci
David Ellinghaus et al.
NATURE GENETICS (2016)
Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis
Carmen Stolwijk et al.
ARTHRITIS CARE & RESEARCH (2016)
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
Walter Reinisch et al.
GUT (2015)
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Jacob S. Lee et al.
IMMUNITY (2015)
Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
Joseph R. Maxwell et al.
IMMUNITY (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
Silvio Danese et al.
GUT (2015)
Decreased Bacterial Diversity Characterizes the Altered Gut Microbiota in Patients With Psoriatic Arthritis, Resembling Dysbiosis in Inflammatory Bowel Disease
Jose U. Scher et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
Tom W. J. Huizinga et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease
Ignazio Olivieri et al.
AUTOIMMUNITY REVIEWS (2014)
Noninvasive Diagnosis of Small Bowel Crohn's Disease: Direct Comparison of Bowel Sonography and Magnetic Resonance Enterography
Fabiana Castiglione et al.
INFLAMMATORY BOWEL DISEASES (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Interleukin-17 Sensitizes Joint Nociceptors to Mechanical Stimuli and Contributes to Arthritic Pain Through Neuronal Interleukin-17 Receptors in Rodents
Frank Richter et al.
ARTHRITIS AND RHEUMATISM (2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
Genetics of spondyloarthritis-beyond the MHC
John D. Reveille
NATURE REVIEWS RHEUMATOLOGY (2012)
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
M. Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Evaluation of the Safety of Rituximab in Combination With a Tumor Necrosis Factor Inhibitor and Methotrexate in Patients With Active Rheumatoid Arthritis Results From a Randomized Controlled Trial
Maria W. Greenwald et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
Rieke Alten et al.
BMC MUSCULOSKELETAL DISORDERS (2011)
Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages
Raja Atreya et al.
GASTROENTEROLOGY (2011)
Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells
Philip P. Ahern et al.
IMMUNITY (2010)
Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis
Norbert Blank et al.
RHEUMATOLOGY (2009)
Emergence of Crohn's Disease During Treatment with the Anti-Tumor Necrosis Factor Agent Etanercept for Ankylosing Spondylitis: Possible Mechanisms of Action
Boulos Haraoui et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2009)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis
M. Gengenbacher et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice
Charles O. Elson et al.
GASTROENTEROLOGY (2007)
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
Michael Weinblatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
Bruce E. Sands et al.
INFLAMMATORY BOWEL DISEASES (2007)
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
Richard H. Duerr et al.
SCIENCE (2006)
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs - A one-year randomized, placebo-controlled study
M. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2006)
Animal models of HLA-B27-associated diseases: new outcomes
C Hacquard-Bouder et al.
JOINT BONE SPINE (2006)
Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis
RJU Lories et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
MC Genovese et al.
ARTHRITIS AND RHEUMATISM (2004)
Infliximab in active early rheumatoid arthritis
FC Breedveld et al.
ANNALS OF THE RHEUMATIC DISEASES (2004)
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis
G Nuki et al.
ARTHRITIS AND RHEUMATISM (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules
M Salmi et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
